1. Oral Products Company:
Developing oral products for viral, bacterial, and fungal infections, including:
- ACE2 Gum: FDA-approved for Phase I/II trials for SARS-CoV-2.
- FRIL Gum: Ongoing Phase I/II trials for SARS-CoV-2, Influenza, and HSV.
- Oral Insulin: Canine insulin trial underway, with human trials planned for 2025.
2. Transdermal Obesity Treatment Company:
Focuses on transdermal drug delivery for obesity and diabetes using advanced polymer technology. Key projects include:
- GLP-1 Agonist (Danuglipron): 99.6% permeation in 6 hours for obesity treatment.
- CB-1 Antagonist (Olivetol): 100% permeation for obesity.
- Upcoming patent filings for transdermal obesity and glucose-controlling agents.
3. Oral Insulin in Lettuce (Plant-Based Delivery):
Developing oral insulin through lettuce plants, targeting canine diabetes with plans for human trials. Preclinical and pilot trials for canine diabetes are projected at $600-650K and $525-600K, respectively.
Unified Funding Request:
- Oral Products Company: Funds for advancing ACE2 gum and oral insulin through Phase I/II trials.
- Transdermal Obesity Treatment Company: Funds for developing GLP-1 agonists, CB-1 antagonists, and filing IND applications.
- Plant-Based Oral Insulin Company: Funds for preclinical and pilot trials for canine diabetes and progression to human trials.